Afrezza is the inhaled insulin developed by MannKind (NASDAQ:MNKD). After the FDA approves Afrezza and after partnership arrangements are finalized, four catalysts will trigger market penetration and commercial success. Three of them involve greater understanding of the significance of (1) how interactive online communities are affecting medical care, (2) how recent research about the physiological processes that result in long-term complications is sparking a paradigm shift that is changing the blood sugar metrics used to guide treatment decisions, and (3) how Afrezza's superior performance on the replacement metrics can protect and enhance the quality of life and long-term health of five groups of people. The fourth catalyst follows logically from the second and third: insurance company acceptance of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|